Redhill Biopharm Stock Price, News & Analysis

RedHill Biopharma (Nasdaq: RDHL) announced its compliance with Nasdaq Listing Rule 5450(a)(1) on April 11, 2023, after maintaining a minimum bid price of $1.00 for ten consecutive trading days, achieving this on April 5, 2023. Previously, on October 12, 2022, RedHill was notified of non-compliance due to its American Depositary Shares (ADSs) closing below the $1.00 requirement. This recent compliance confirms its eligibility for continued listing on Nasdaq, which is crucial for maintaining investor confidence and market access.

RedHill is focused on gastrointestinal and infectious diseases, promoting drugs such as Talicia® and Aemcolo®. Ongoing late-stage clinical developments include studies for RHB-204 and RHB-107, targeting various health conditions.

The report titled "Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2023" has been released by ResearchAndMarkets.com. This comprehensive report offers insights into partnering deals in the pharmaceutical and biotechnology sectors, including details on technology licensed, royalty rates, license fees, and other payments. It covers all disclosed deals since 2010, providing essential data for prospective dealmakers. Key chapters analyze royalty rate trends, the structure of royalty clauses, and leading companies in the field. The report aims to equip readers with the necessary tools for effective negotiations and due diligence in licensing agreements.

On April 3, 2023, RedHill Biopharma (Nasdaq: RDHL) announced the closure of a registered direct offering, raising $6 million. The offering included 1,500,000 American Depositary Shares (ADSs) and series A and B warrants, with respective exercise prices of $4.75 and $4.00. The proceeds will be utilized for general working capital, acquisitions, and research and development. Additionally, existing warrants for 330,106 ADSs were amended to lower the exercise price to $4.75. H.C. Wainwright & Co. was the exclusive placement agent for this offering.

The Non-Cystic Fibrosis Bronchiectasis (NCFB) market is projected to grow significantly from USD 3.4 billion in 2022, driven by increased awareness and diagnosis of the condition. Current estimates indicate around 9.3 million diagnosed cases across the 7MM and China. Prominent companies, including AstraZeneca and CSL Behring, are developing innovative therapies, with several promising drugs in the pipeline, such as Brensocatib and Colistimethate sodium. Despite rising disease prevalence and improved diagnostic techniques, challenges remain, including a lack of standardized treatment guidelines and insufficient evidence for many interventions.

RedHill Biopharma (NASDAQ: RDHL) announced a definitive agreement for a registered direct offering of 1,500,000 American Depositary Shares (ADSs) at $4.00 each, expected to generate gross proceeds of $6 million. The offering includes series A and B warrants to purchase additional ADSs. The proceeds are earmarked for general working capital, acquisitions, research and development, and corporate purposes. The offering is expected to close on April 3, 2023. Additionally, existing warrants for 330,106 ADSs will be amended to reduce the exercise price to $4.75.

RedHill Biopharma has launched a pioneering warranty program for its Talicia H. pylori therapy, committing to reimburse out-of-pocket costs for patients who complete a 14-day treatment but do not achieve infection eradication. This initiative, applicable to both insured and non-insured patients, aims to enhance access to Talicia, which boasts a cure rate exceeding 90% in adherent populations. The program marks a first in community settings and seeks to address rising resistance to traditional therapies. Notably, Talicia is the leading prescribed option among U.S. gastroenterologists, indicating strong market positioning.

RedHill Biopharma (Nasdaq: RDHL) announced a change in the ratio of its American Depositary Shares (ADSs) to ordinary shares, shifting from 1:10 to 1:400. This is akin to a one-for-forty reverse split and will take effect on or about March 23, 2023. The Bank of New York Mellon will manage the conversion for ADS holders, with no action required on their part. This change aims to increase the ADS price and help meet Nasdaq's minimum bid price requirements, following a notification received on October 18, 2022. However, there is no guarantee that the anticipated price increase will occur.